CN102080086B - Human miR-133a antisense nucleic acid and application thereof - Google Patents
Human miR-133a antisense nucleic acid and application thereof Download PDFInfo
- Publication number
- CN102080086B CN102080086B CN 200910199732 CN200910199732A CN102080086B CN 102080086 B CN102080086 B CN 102080086B CN 200910199732 CN200910199732 CN 200910199732 CN 200910199732 A CN200910199732 A CN 200910199732A CN 102080086 B CN102080086 B CN 102080086B
- Authority
- CN
- China
- Prior art keywords
- mir
- antisense oligonucleotide
- modification
- sequence
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开一种抑制人microRNA-133a表达的反义寡聚核苷酸及其应用。该反义寡聚核苷酸特异性结合于人miR-133a，包含与下述核苷酸序列中13～22个连续核苷酸互补的序列：5’-UUUGGUCCCCUUCAACCAGCUG-3’，特别是其包含序列：5’-CAGCUGGUUGAAGGGGACCAAA-3’。本发明的反义寡聚核苷酸可以为核糖核苷酸、脱氧核糖核苷酸或核糖核苷酸与脱氧核糖核苷酸的嵌合体，并可对链中任一核苷酸进行修饰。本发明的miR-133a反义寡核苷酸能够有效抑制人脑胶质瘤细胞中miR-133a表达，抑制其生长和增殖，从而有效治疗脑胶质瘤及其他miR-133a高表达的肿瘤。The invention discloses an antisense oligonucleotide for inhibiting the expression of human microRNA-133a and its application. The antisense oligonucleotide specifically binds to human miR-133a, and includes a sequence complementary to 13 to 22 consecutive nucleotides in the following nucleotide sequence: 5'-UUUGGUCCCCUUCAACCAGCUG-3', especially it includes Sequence: 5'-CAGCUGGUUGAAGGGGACCAAA-3'. The antisense oligonucleotide of the present invention can be ribonucleotide, deoxyribonucleotide or chimera of ribonucleotide and deoxyribonucleotide, and any nucleotide in the chain can be modified. The miR-133a antisense oligonucleotide of the present invention can effectively inhibit the expression of miR-133a in human brain glioma cells, inhibit its growth and proliferation, thereby effectively treating brain glioma and other tumors with high miR-133a expression.
Description
Technical field
The invention belongs to technical field of biomedical materials and pharmaceutical field.Particularly, the present invention relates to the purposes of a kind of microRNAs (miRNA), especially relate to people microRNA-133a (people miR-133a) antisense nucleic acid and application thereof.This antisense nucleic acid can be complementary with people miR-133a, thereby suppress the expression of people miR-133a and play antineoplastic action.The invention still further relates to the pharmaceutical composition that contains this miRNA antisense nucleic acid.
Background technology
MiRNAs is little non-coding RNA, and length is 20-25bp, is normally transcribed by rna plymerase ii (PolII), and general initial product is the big pri-miRNA with cap sequence (7MGpppG) and polyadenylic acid tail (AAAAA).These pri-miRNA are processed into the pre-miRNA precursor product that 70 Nucleotide are formed under the effect of RNase III Drosha and its cofactor Pasha.RAN-GTP and exportin 5 are transported to this precursor molecule in the tenuigenin.Subsequently, another RNase III Dicer shears it and produces the two strands that is about 22 length of nucleotides.This two strands is directed in (miRISC) complex body very soon, wherein contains Argonaute albumen, and sophisticated strand miRNA is retained in this mixture.Sophisticated miRNA is attached to the site of its complementary mRNA and expresses through two kinds of machine-processed negative regulator genes that depend on the sequence complementarity, on the protein translation level, suppresses its expression with the incomplete complementary miRNA of said target mrna.Yet, evidence suggests also that recently these miRNA also might influence the stability of mRNA.Use the miRNA binding site of this mechanism to hold non-translational region at 3 ' of mRNA usually.If miRNA and target site complementary fully (perhaps almost completely complementary), the combination of these miRNA often causes the degraded of target molecule mRNA so.MiRNAs is quite conservative in spore, and animal, the miRNAs that finds in plant and the fungi etc. expresses all has strict tissue specificity and sequential property.
At present, have only the biological function of very little a part of miRNAs to be illustrated.These miRNAs regulate cell growth and tissue differentiation, and are relevant with biological growth and development.A series of research shows: miRNAs is at cell growth and apoptosis, and hemocyte breaks up, the homeobox generegulation, and neuronic polarity, insulin secretion, the brain form forms, and heart takes place, and plays a significant role in the processes such as late embryogenesis growth.For example, miR-273 participates in the nervous system development process of nematode; MiR-430 participates in the brain development of zebra fish; MiR-181 control Mammals hematopoietic cell is divided into the B cell; MiR-375 regulates mammalian islet cell and grows and insulin secretion; MiR-143 works in the adipocyte differentiation; MiR-196 has participated in the Mammals four limbs and has formed, and miR-1 is relevant with heart development.Other has the researchist to find that many neural miRNAs receive sequential and regulate in pallium is cultivated, and shows its mRNA that possibly control compartmentation translation.
MiRNA expresses relevant with multiple cancer, and these genes possibly play tumor suppressor gene or oncogene effect.In B cell chronic lymphatic leukemia (CLL), find to have the change of miRNA expression level at first, in various human tumors, all detect the miRNA changes of expression level subsequently successively.Discover that it is relevant that miRNAs and tumour form, and can bring into play the effect (like miR-15a and miR-16-1) of tumor suppressor gene, can play the effect (like miR-155 and miR-17-92 bunch) of oncogene again.Think at present, in tumour cell, ripe body of some miRNA or precursor expression horizontal abnormality, and the miRNA of abnormal expression plays a role through influencing the said target mrna translation, participates in neoplastic process, and plays an important role.Receive the regulation and control of let-7 family like the Ras proto-oncogene, the BCL2 anti-apoptotic genes expression receives miR-15a-miR-16-1 bunch of regulation and control, and the E2F1 transcription factor receives miR-17-92 bunch of regulation and control, and the BCL6 anti-apoptotic genes expression receives the regulation and control of miR-127 etc.The down-regulated expression of miRNAs also has substantial connection with tumour, and this is indicating that miRNA has the function of oncogene.For example, miR-143 and miR-145 obviously downward modulation in colorectal carcinoma.What is interesting is that the precursor molecule of its hairpin structure content in tumour and healthy tissues is similar, this shows that the down-regulated expression of miRNAs possibly be because its course of processing is damaged.But the tumor suppressor gene function of miR-143 and miR-145 possibly not only be confined to colorectal carcinoma, also obviously downward modulation of its expression amount in clones such as mammary cancer, prostate cancer, uterus carcinoma, lymphatic cancer.Another report shows that miR-21 expresses increase in glioblastoma multiforme.The expression amount of this gene in tumor tissues than high 5-100 in healthy tissues doubly.
MiRNAs is natural antisense acting factor, can regulate and control the several genes relevant with propagation with eukaryote existence.Aspect oncotherapy, the application prospect of miRNA is bright.Utilizing miRNA as aspect the treatment target spot, existing experimental data support:, the variation of miRNA express spectra occurs as in the process of gemcitabine (gemcitabine) treatment; The expression level (as making miR-21 cross expression) of regulation and control part miRNA can be promoted the susceptibility of cholangiocarcinoma cell to chemotherapeutics.MiRNAs through in the possible effectively deactivation tumour of introducing and the miRNA complementary synthetic antisense oligonucleotide---anti-miRNA oligonucleotide (AMOs)---with oncogene characteristic delays its growth.Clinically, can methylate or lock nucleic acid modified antisense oligonucleotide administrations such as (LNA) through 2 '-O-frequent or that continue and make the miRNA inactivation.These modifications make oligonucleotide more stable, and are lower than other treatment means toxicity.Use antagomirs (with SUV link coupled AMOs), can effectively suppress the miRNA activity in Different Organs behind the injection mouse, thereby possibly become a kind of medicine likely.Opposite, cross and express the miRNAs that those have the tumor suppressor gene effect, like let-7 family, also can be used to treat some specific tumour.
Antisense oligonucleotide (Flanagan WM.Antisense comes of age.Cancer&Metastasis Reviews 1998; 17 (2): 169-76) be meant one section can with the Nucleotide of the base complementrity of its target gene.Antisense oligonucleotide can be answered expression of gene by inhibitory phase.
People microRNA-133a (hsa-mir-133a) precursor sequence has two; Be respectively hsa-mir-133a-1; Be positioned on No. 18 karyomit(e), sequence is ACAAUGCUUUGCUAGAGCUGGUAAAAUGGAACCAAAUCGCCUCUUCAAUGGAUUUG GUCCCCUUCAACCAGCUGUAGCUAUGCAUUGA; And hsa-mir-133a-2; Be positioned on No. 20 karyomit(e); Sequence is GGGAGCCAAAUGCUUUGCUAGAGCUGGUAAAAUGGAACCAAAUCGACUGUCCAAUG GAUUUGGUCCCCUUCAACCAGCUGUAGCUGUGCAUUGAUGGCGCCG; But these two precursors are only expressed a ripe body hsa-miR-133a, and sequence is UUUGGUCCCCUUCAACCAGCUG.Employing Micro chips such as Amdt are analyzed the expression of miRNA in the colorectal cancer, and research is illustrated in 45 colorectal carcinoma tissue samples, and it is significantly reduced that the expression level of mir-133a is compared with healthy tissues.Usefulness TaqMan real-time PCR such as Childs find also that in Head and Neck squamous cell cancer tissue the mir-133a expression level is significantly to descend.Ichimi etc. find that in Bladder Cancer miR-133a is significantly reduced; The miR-145 in addition of expression level decline simultaneously; MiR-30a-3p, 7 miRNAs such as miR-199a*, what also have the meaning is; They find have 3 miRNAs (miR-30-3p, miR-133a and miR-199a*) can both suppress the mRNA level of KRT7 among 7 miRNA of this downward modulation.But also not about the function of mir-193b in glioma and the research report of expression level.(Arndt，Dossey?et?al.2009；Childs，Fazzari?et?al.2009；Ichimi，Enokidaet?al.2009)
Nearly 30 years although the complex therapy of tumour is very general clinically, is main with operation; Chemicotherapy is that the complex therapy of assisting is also not obvious to the survival rate raising of tumour patient; Overall survival rate was still lower in 5 years, paced up and down about 30%～55%, did not significantly improve; 5 years survival rates of middle and advanced stage patient are lower, are about 20%.And all there are limitation separately in these methods, particularly to middle and advanced stage and recurrence patient unsatisfactory curative effect, to poorer with metastasis person's curative effect.Therefore, seeking safer and more effective treatment approach is the difficult problem that raising tumour patient survival rate and life quality are needed to be resolved hurrily.
Summary of the invention
The subject matter that the present invention will solve just provides the antisense nucleic acid (suppressor factor) of one group of new miR-133a; Be used for efficient, low toxicity or suppress the expression of miR-133a innocuously; And then treat the disease that causes by the miR-133a over-expresses, and comprise tumour, especially be cerebral glioma.
Another problem that the present invention will solve just provides the purposes of above-mentioned antisense oligonucleotide in the medicine of the relative disease of preparation treatment mir-133a over-expresses.
The problem again that the present invention will solve provides a kind of pharmaceutical composition that comprises above-mentioned antisense nucleic acid.
The inventor has designed and synthesized the length different antisense nucleic acid of a series of specificitys to the miR-133a different zones through extensive and deep research, and checking has the antisense nucleic acid that suppresses effect in culturing cell.Research shows that these antisense nucleic acides can suppress the growth and the malignant proliferation ability of tumour cell.
The present invention has designed a series of antisense nucleic acid molecules that can be incorporated into the miR-133a different positions; In culturing cell U87/MG; The antisense nucleic acid cell growth ability that checking suppresses the miR-133a expression specificity, the influence of multiplication capacity; Antisense nucleic acid molecule length can comprise 13～22 nucleotide residues; Inhibition growth of human tumor cells ability in various degree, the characteristic of multiplication capacity are all arranged, and wherein the shortest antisense nucleic acid length is 13 bases, and the antisense nucleic acid of different lengths all has good growth of tumour cell and proliferation inhibition activity.Therefore, above-mentioned antisense nucleic acid all can be used to prepare the preparation that suppresses growth of tumour cell ability, multiplication capacity, the wherein tumour cell of preferred miR-133a high expression level.Accomplished the present invention on this basis.
First aspect of the present invention provides the antisense oligonucleotide of a kind of miR-133a, and said antisense oligonucleotide suppresses the expression of miR-133a in people's cell.Usually, continuous 13～22 nucleotide sequence complementations among said antisense oligonucleotide and the 5 '-UUUGGUCCCCUUCAACCAGCUG-3 '.In a preferred embodiment of the invention, the length of said antisense oligonucleotide is 18～22 Nucleotide.More preferably, the sequence of said antisense oligonucleotide is 5 ' CAGCUGGUUGAAGGGGACCAAA-3 '.
At present, RNA is higher than the avidity of DNA and miRNA hybridization with the hybridization avidity of miRNA in the nucleic acid hybridization, has very high pharmaceutical use.But artificial-synthetic DNA's the cost cost than synthetic RNA far away is low, also has good market potential.And can adopt the chimeric antisense nucleic acid that forms that links to each other of ribose RNA monomer and ribodesose dna single body to develop as medicine.A series of antisense nucleic acid molecules of the present invention's design had both comprised dna molecular, also comprised the RNA molecule, and two kinds of molecules all have the activity that suppresses the miR-133a expression.
The antisense nucleic acid of the present invention's design, it is active that its sequence has specific biological, and its antisense nucleic acid institute complementary length for the site of a certain gene complementation has much relations; Long like complementary; Then BA can be higher, and suppressing effect also can be more better, increasing or reducing an antisense nucleic acid that is complementary to same gene locus to several bases; Equally also has BA in various degree; Also can reach in various degree inhibition growth of tumour cell and the effect of propagation, research of the present invention shows, weak point can reach 13 bases and still have the effect that miR-133a expresses that suppresses.In the antisense nucleic acid research, various chemical modification methods are a lot, comprise one or more the combination etc. that is selected from ribose modification, base modification and the phosphoric acid backbone modification.Will be clear that any modifying method that can increase antisense nucleic acid stability and bioavailability can use, like SUV modification, PEG modification, thio-modification, 2 '-methoxyl group modification etc.Antisense oligonucleotide described in this paper is modified through 2 ' methoxyl group.
Above-mentioned antisense nucleic acid of the present invention has the effect that suppresses the miR-133a expression.When with after above-mentioned antisense nucleic acid transfection is in the cell strain U87 of miR-133a high expression level, can effectively suppress the growth and the malignant proliferation ability of tumour cell.
The present invention also provides a kind of pharmaceutical composition, and it contains oligonucleotide of the present invention and the pharmaceutically acceptable carrier or the vehicle of safe and effective amount.This type carrier includes but not limited to: salt solution, damping fluid, glucose, water, glycerine, ethanol and combination thereof.Pharmaceutical prepn should be complementary with administering mode.Pharmaceutical composition of the present invention can be made into the injection form, for example prepares through ordinary method with the saline water or the aqueous solution that contains glucose and other assistant agents.
Said " significant quantity " is meant and can produces function or amount active and that can be accepted by people and/or animal to people and/or animal.
Said " pharmaceutically acceptable " composition is applicable to people and/or animal and does not have excessive bad side reaction (like toxicity, stimulation and transformation reactions), the material of rational benefit/risk ratio is promptly arranged.
In the third aspect of the invention, the purposes of antisense oligonucleotide of the present invention is provided, be used to prepare the medicine of treating following disease: treatment human body and miR-133a cross the expression diseases associated, comprise tumour, are preferably cerebral glioma.
As used herein, " antisense oligonucleotide " refers to the nucleotide oligomer of antisense.Antisense oligonucleotide through base complementrity (G-C) pairing forms three chains (anti-gene) with double-stranded DNA for A-T, A-U, or forms heteroduplex (antisense) with single stranded RNA, thus the processing and the translation of duplicating, transcribing or transcribing back mRNA of blocking gene.Simultaneously, double-stranded RNA can be degraded by intracellular ribonuclease H (RNaseH), thereby more effectively blocks target gene expression.Because GEM 132 can only combine with the target sequence of reverse complemental, has the specificity height, the characteristics that spinoff is little.
The not special restriction of the length of antisense oligonucleotide of the present invention, in general, in order to reach the specificity of hybridization, the Nucleotide that antisense oligonucleotide needs at least 13 monomers to form.Usually the length of antisense oligonucleotide is 13～35bp, and for the ripe body of miRNA, preferable antisense oligonucleotide length is 18～22bp.
Description of drawings
Fig. 1 has shown that the miR-133a antisense oligonucleotide suppresses the growth and the propagation of tumour cell U87/MG cell, the U87/MG cell behind A, B the be transfection negative control of FAM mark; C is transfection negative control (5 '-CAGUACUUUUGUGUAGUACAA-3 ') back U87/MG cell state; D is transfection miR-133a antisense oligonucleotide (5 '-CAGCUGGUUGAAGGGGACCAAA-3 ') back U87/MG cell state.
Embodiment
Antisense oligonucleotide of the present invention, continuous 13～22 nucleotide sequence complementations among its sequence and 5 '-UUUGGUCCCCUUCAACCAGCUG-3 ', and also not complementary with the RNA sequence of other genes.In a preferred embodiment of the invention, the sequence of said antisense oligonucleotide be 5 '-CAGCUGGUUGAAGGGGACCAAA-3 '.Antisense oligonucleotide provided by the invention can be modified outcome; It contains at least two, and at least 4 usually, preferable at least 6; At least 8 better Nucleotide do not have the Nucleotide of the modification of toxic side effects, and said modification mode comprises 2 ' methoxyl group replacement, thio-modification etc.In order to increase the cellular uptake rate of antisense oligonucleotide, can also on the basis of above-mentioned modification, carry out SUV and modify or the PEGization modification antisense oligonucleotide.Oligonucleotide after the above-mentioned modification can continue effectively to match with target sequence, and has the longer transformation period in vivo than common Yeast Nucleic Acid or thymus nucleic acid without modifying.
The present invention has following advantage:
1, antisense oligonucleotide acts on specific target site, the site of non-specific binding seldom, specificity is high;
2, antisense oligonucleotide provided by the invention is through suitable chemically modified, has that toxicity is low, spinoff is little and characteristics such as long half time;
3, antisense oligonucleotide provided by the invention has the good restraining effect, and the inhibiting rate of growth of tumour cell is surpassed 40%.
To combine embodiment and accompanying drawing to describe the present invention in further detail below.Yet should be appreciated that and enumerate these embodiment, and be not to be used for limiting scope of the present invention just for an illustration.
Embodiment
Embodiment 1, miR-133a antisense oligonucleotide suppress active to human neuroglia glucagonoma clone U87/MG and detect
At first, by the synthetic miR-133a antisense oligonucleotide of Shanghai JiMa pharmacy Technology Co., Ltd, sequence is: 5 '-CAGCUGGUUGAAGGGGACCAAA-3 '.The used sequence that relates in an embodiment is synthetic by Shanghai JiMa pharmacy Technology Co., Ltd.
Cell cultures:
U87/MG cell (available from typical case's culture collection council of Chinese Academy of Sciences cell bank), 10%FBS-DMEM substratum (FBS is available from Gibco, and DMEM is available from Hyclone) is cultivated, and 37 ℃, 5%CO
2Cultivate.Collect the good U87/MG cell of growth conditions, centrifugal counting is with 2 * 10
3Every hole is laid in 96 orifice plates, and 37 ℃, 5%CO
2Cultivate 24h.
Transfection:
1) transfection previous day, with not containing antibiotic culture medium inoculated culturing cell in right amount, the degree of converging of cell reaches 30～50% when making transfection in 96 orifice plates;
2) the transfection sample is prepared oligomer-Lipofecta mine according to following method
TM2000 mixtures:
A.
the I substratum (Gibco) that does not contain serum with 25 μ l dilutes the negative control of miR-133a antisense oligonucleotide (5 '-CAGCUGGUUGAAGGGGACCAAA-3 '), negative control (5 '-CAGUACUUUUGUGUAGUACAA-3 '), FAM mark respectively; Final concentration is 50nM after adding in the hand-hole; Mixing gently, each transfection are established 3 multiple holes;
B. mixing Lipofecta mine gently before using
TM2000 (Invitrogen) get 0.25 μ l then and are diluted to 25 μ l's
The I substratum is at room temperature hatched 5min gently behind the mixing;
C. after hatching 5min, the Lipofecta mine of dilution
TM2000 mix with the GEM 132 and the contrast of dilution respectively, at room temperature hatch 20min gently behind the mixing, to allow the formation of mixture;
3) mixture is joined in each hole that comprises cell and substratum, the culture plate that rocks back and forth lightly mixes; The final concentration of GEM 132 and contrast is 50nM.
4) 37 ℃, 5%CO
2After incubator continued to hatch 72 hours, microscopic examination U87/MG cell was taken a picture.
As shown in Figure 1, transfection is after 72 hours, surpass 80% U87/MG cell success transfection the negative control of FAM mark (figure A, B); Behind the transfection negative control, the U87/MG cell is complete, light transmission strong (figure C); Most of U87/MG necrocytosis behind the transfection miR-133a antisense oligonucleotide (figure D).
Cytotoxicity experiment based on MTT:
The cell that upwards obtains in the step adds MTT (Sigma) 5mg/ml (the saline water preparation with 0.9%) for preparing, and every hole adds 20 μ l, 37 ℃, 5%CO
2Hatch after 4 hours to inhale and remove substratum and MTT, every hole adds DMSO 100 μ l and reads the absorbance of OD570-OD630 through ELIASA.
Calculate inhibiting rate:
The inhibiting rate that calculates the cell growth is 41.11 ± 4.85%.
The result shows: miR-133a antisense oligonucleotide provided by the invention has the good restraining effect, and the inhibiting rate that U87/MG is grown surpasses 40%.
Sequence table
< 110>Shanghai Pharmaceutical Inst., Chinese Academy of Sciences
Suzhou JiMa gene medicine Science Co., Ltd
< 120>people miR-133a antisense nucleic acid and application thereof
<130>DI09-1419-XC37
<160>5
<170>PatentIn?version?3.3
<210>1
<211>88
<212>RNA
<213>hsa-mir-133a-1
<400>1
acaaugcuuu?gcuagagcug?guaaaaugga?accaaaucgc?cucuucaaug?gauuuggucc 60
ccuucaacca?gcuguagcua?ugcauuga 88
<210>2
<211>102
<212>RNA
<213>hsa-mir-133a-2
<400>2
gggagccaaa?ugcuuugcua?gagcugguaa?aauggaacca?aaucgacugu?ccaauggauu 60
ugguccccuu?caaccagcug?uagcugugca?uugauggcgc?cg 102
<210>3
<211>22
<212>RNA
< 213>ripe body hsa-miR-133a
<400>3
uuuggucccc?uucaaccagc?ug 22
<210>4
<211>22
<212>RNA
< 213>artificial sequence
<220>
< 223>antisense oligonucleotide
<400>4
cagcugguug?aaggggacca?aa 22
<210>5
<211>21
<212>RNA
< 213>artificial sequence
<220>
< 223>negative control antisense oligonucleotide
<400>5
caguacuuuu?guguaguaca?a 21
Claims (6)
1. an antisense oligonucleotide is used to prepare the purposes of the medicine of treating cerebral glioma; Wherein, said antisense oligonucleotide sequence is the chimeric sequence with 5 '-UUUGGUCCCCUUCAACCAGCUG-3 ' nucleotide sequence complementary ribonucleoside acid sequence, deoxyribonucleotide sequence or ribonucleotide and deoxyribonucleotide.
2. purposes as claimed in claim 1 is characterized in that, said antisense oligonucleotide sequence is 5 '-CAGCUGGUUGAAGGGGACCAAA-3 '.
3. according to claim 1 or claim 2 purposes is characterized in that said antisense oligonucleotide is further modified.
4. purposes as claimed in claim 3 is characterized in that, said modification is selected from one or more the combination in ribose modification, base modification and the phosphoric acid backbone modification.
5. purposes as claimed in claim 4 is characterized in that, said modification is selected from one or more in thio-modification, 2 '-methoxyl group modification and the SUV modification.
6. purposes as claimed in claim 1 is characterized in that, said antisense oligonucleotide and other treatment are medication combined to be used.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200910199732 CN102080086B (en) | 2009-12-01 | 2009-12-01 | Human miR-133a antisense nucleic acid and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200910199732 CN102080086B (en) | 2009-12-01 | 2009-12-01 | Human miR-133a antisense nucleic acid and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102080086A CN102080086A (en) | 2011-06-01 |
| CN102080086B true CN102080086B (en) | 2012-12-26 |
Family
ID=44086278
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200910199732 Active CN102080086B (en) | 2009-12-01 | 2009-12-01 | Human miR-133a antisense nucleic acid and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102080086B (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11260072B2 (en) | 2011-09-07 | 2022-03-01 | 3-D Matrix, Ltd. | MicroRNA-based methods and assays for osteocarcinoma |
| US9322016B2 (en) * | 2011-09-07 | 2016-04-26 | 3-D Matrix Ltd. | MicroRNA-based methods and assays for osteosarcoma |
| US10905708B2 (en) | 2011-09-07 | 2021-02-02 | 3-D Matrix, Ltd. | MicroRNA-based methods and assays for osteocarcinoma |
| WO2013037065A1 (en) * | 2011-09-13 | 2013-03-21 | Ottawa Hospital Research Institute | Microrna inhibitors |
| EP2604690A1 (en) * | 2011-12-15 | 2013-06-19 | Oncostamen S.r.l. | MicroRNAs and uses thereof |
| US20140356459A1 (en) * | 2011-12-15 | 2014-12-04 | Oncostamen S.R.L. | Micrornas and uses thereof |
| CN103961720B (en) * | 2013-03-19 | 2016-03-02 | 广州中国科学院先进技术研究所 | MicroRNA is for the preparation of reducing glioma to the purposes of the medicine of TRAIL toleration |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101091798A (en) * | 2007-04-17 | 2007-12-26 | 华东师范大学 | Application of meaning inversed miRNA-210 |
| WO2009033140A1 (en) * | 2007-09-06 | 2009-03-12 | The Ohio State University Research Foundation | Microrna signatures in human ovarian cancer |
| WO2009036236A1 (en) * | 2007-09-14 | 2009-03-19 | The Ohio State University Research Foundation | Mirna expression in human peripheral blood microvesicles and uses thereof |
-
2009
- 2009-12-01 CN CN 200910199732 patent/CN102080086B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101091798A (en) * | 2007-04-17 | 2007-12-26 | 华东师范大学 | Application of meaning inversed miRNA-210 |
| WO2009033140A1 (en) * | 2007-09-06 | 2009-03-12 | The Ohio State University Research Foundation | Microrna signatures in human ovarian cancer |
| WO2009036236A1 (en) * | 2007-09-14 | 2009-03-19 | The Ohio State University Research Foundation | Mirna expression in human peripheral blood microvesicles and uses thereof |
Non-Patent Citations (4)
| Title |
|---|
| Hilah Gal et al..MIR-451 and Imatinib mesylate inhibit tumor growth of Glioblastoma stem cells.《Biochemical and Biophysical Research Communications》.2008,第376卷86-90. * |
| John J. McCarthy and Karyn A. Esser.MicroRNA-1 and microRNA-133a expression are decreased during skeletal muscle hypertrophy.《Journal of Applied Physiology》.2006,第102卷306-313. * |
| 易伟峰.Micro RNA在胶质瘤组织表达差异谱的研究.《中国现代医学杂志》.2009,第19卷(第8期),1152-1155. * |
| 杨鹏远.反义寡核苷酸类药物的研究进展.《国外医学药学分册》.2002,第29卷(第4期),193-197. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102080086A (en) | 2011-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102080086B (en) | Human miR-133a antisense nucleic acid and application thereof | |
| CN102382824A (en) | Human miR-145 antisense nucleic acid and application thereof | |
| CN102031256B (en) | Human miR-485-5p antisense nucleic acid and application thereof | |
| CN101993877A (en) | Human miR-296-5p antisense nucleic acid and application thereof | |
| CN102080085A (en) | Human miR-193b antisense nucleotide and application thereof | |
| CN102140469B (en) | Human miR (microRNA)-1233 antisensenucleic acid and application thereof | |
| CN102080083B (en) | Human miR-149 antisense nucleic acid and its application | |
| CN102140464B (en) | Human miR-1238 antisense nucleic acid and applications thereof | |
| CN102080082B (en) | Human miR-129* antisensenucleic acid and applications thereof | |
| CN102140467B (en) | Human miR-365 antisense nucleic acid and its application | |
| CN102031254B (en) | Human miR-150 antisense nucleic acid and application thereof | |
| CN102643809B (en) | The antisense oligonucleotide of people miR-1274b and application thereof | |
| CN102643807B (en) | Antisense oligodeoxyncleotide of human miR-484 and application thereof | |
| CN102140465B (en) | Human miR-1249 antisense nucleic acid and application thereof | |
| CN102382825B (en) | Human miR-1826 antisense nucleic acid and its application | |
| CN102643814B (en) | Antisense oligonucleotide for human miR-431 and application thereof | |
| CN102643806B (en) | The antisense oligonucleotide of people miR-1913 and application thereof | |
| CN102140462B (en) | Human miR-1260 antisense nucleic acid and application thereof | |
| CN102140470B (en) | Human miR-1236 antisense ribonucleic acid and application thereof | |
| CN102643811A (en) | Human miR-1229 antisense oligonucleotide and application thereof | |
| CN102643810B (en) | The antisense oligonucleotide of people miR-299-5p and application thereof | |
| CN102643813B (en) | The antisense oligonucleotide of people miR-504 and application thereof | |
| CN102031255B (en) | Antisense nucleic acid of human miR-223 and applications of antisense nucleic acid | |
| CN102041256B (en) | Human miR-486-5p antisense nucleic acid and application thereof | |
| CN102080084B (en) | Human miR-125a-5p antisense nucleic acid and its application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |